GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » Operating Income

Angion Biomedica (Angion Biomedica) Operating Income : $-23.80 Mil (TTM As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica Operating Income?

Angion Biomedica's Operating Income for the three months ended in Mar. 2023 was $-4.61 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 was $-23.80 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Angion Biomedica's Operating Income for the three months ended in Mar. 2023 was $-4.61 Mil. Angion Biomedica's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, Angion Biomedica's Operating Margin % for the quarter that ended in Mar. 2023 was %.

Angion Biomedica's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Angion Biomedica's annualized ROC % for the quarter that ended in Mar. 2023 was -274.33%. Angion Biomedica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -6,688.93%.


Angion Biomedica Operating Income Historical Data

The historical data trend for Angion Biomedica's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angion Biomedica Operating Income Chart

Angion Biomedica Annual Data
Trend Dec12 Dec13 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Income
Get a 7-Day Free Trial -14.34 -38.59 -55.27 -39.31 -30.44

Angion Biomedica Quarterly Data
Jun13 Dec13 Mar14 Jun14 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.49 -9.04 -6.25 -3.91 -4.61

Angion Biomedica Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Angion Biomedica  (NAS:ANGN) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Angion Biomedica's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

ROC % (Q: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Mar. 2023 ))/ count )
=-18.428 * ( 1 - 0% )/( (2.552 + 10.883)/ 2 )
=-18.428/6.7175
=-274.33 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Angion Biomedica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-18.428/( ( (0.425 + max(-4.67, 0)) + (0.126 + max(-0.379, 0)) )/ 2 )
=-18.428/( ( 0.425 + 0.126 )/ 2 )
=-18.428/0.2755
=-6,688.93 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.638) - (5.177 + 0 + 0.131)
=-4.67

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.425) - (1.665 + 0 + 0.139)
=-0.379

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Angion Biomedica's Operating Margin % for the quarter that ended in Mar. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-4.607/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Angion Biomedica Operating Income Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Angion Biomedica (Angion Biomedica) Business Description

Traded in Other Exchanges
N/A
Address
7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459
Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Executives
Jay Venkatesan director, officer: See Remarks C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson director 601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan officer: See Remarks 750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan officer: See Remarks 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes officer: See Remarks C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg officer: See Remarks 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi director
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc 10 percent owner C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553

Angion Biomedica (Angion Biomedica) Headlines